Zhang et al. showed that the synthetic peptide R11-p53c can be effectively and preferentially delivered into bladder cancer cells, resulting in the reactivation of the p53 gene and inhibition of tumor growth. This evidence concerns the gene TP53 and urinary bladder cancer.